AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22219223 — intervention group
Group type: COMPARATOR
Intervention: T-cell responses to HIV-1 or other underlying infections
Number of subjects: 0
Study 22221511 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramedullary nailing (IMN)
Number of subjects: 12
Study 22221738 — intervention group
Group type: EXPERIMENTAL
Intervention: Condom distribution and peer education intervention in high risk venues
Number of subjects: 72
Study 22221738 — intervention group
Group type: COMPARATOR
Intervention: Control community
Number of subjects: 72
Study 22222076 — intervention group
Group type: EXPERIMENTAL
Intervention: MitraClip procedure
Number of subjects: 78
Study 22222076 — intervention group
Group type: COMPARATOR
Intervention: Standard care (comparator group)
Number of subjects: 78
Study 22222143 — intervention group
Group type: EXPERIMENTAL
Intervention: Myotonometric measurement of muscle tone, elasticity, and stiffness
Number of subjects: 67
Study 22222175 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar manic patients carrying the Met allele
Number of subjects: 64
Study 22222175 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar depressed patients with the Met allele
Number of subjects: 64
Study 22222175 — intervention group
Group type: COMPARATOR
Intervention: Healthy homozygous subjects with the Met allele
Number of subjects: 64
Study 22223235 — intervention group
Group type: EXPERIMENTAL
Intervention: tPA plus Argatroban (100-μg/kg bolus and infusion for 48 hours)
Number of subjects: 65
Study 22223235 — intervention group
Group type: EXPERIMENTAL
Intervention: tPA plus Argatroban
Number of subjects: 65
Study 22223821 — intervention group
Group type: EXPERIMENTAL
Intervention: rFVIIIFc (recombinant factor VIII Fc fusion protein) at doses of 25 or 65 IU/kg
Number of subjects: 16
Study 22223821 — intervention group
Group type: COMPARATOR
Intervention: rFVIII (standard factor VIII product)
Number of subjects: 16
Study 22223838 — intervention group
Group type: EXPERIMENTAL
Intervention: Early sexual debut (15 years or younger)
Number of subjects: 3492
Study 22223838 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall risk factors considered
Number of subjects: 3492
Study 22225488 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT) with 1, 3, or 5 fractions for median doses of 18, 27, and 30 Gy respectively.
Number of subjects: 93
Study 22225488 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT)
Number of subjects: 93
Study 22225857 — intervention group
Group type: EXPERIMENTAL
Intervention: 30mg of pioglitazone alone
Number of subjects: 40
Study 22225857 — intervention group
Group type: EXPERIMENTAL
Intervention: 30mg of pioglitazone after 81mg of aspirin
Number of subjects: 40
Study 22228003 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza A/H1N1/09 vaccination in children with celiac disease
Number of subjects: 14
Study 22228003 — intervention group
Group type: COMPARATOR
Intervention: Control group (age-/sex-matched)
Number of subjects: 14
Study 22228076 — intervention group
Group type: EXPERIMENTAL
Intervention: Malawian infants
Number of subjects: 75
Study 22228076 — intervention group
Group type: COMPARATOR
Intervention: Finnish infants
Number of subjects: 75
Study 22228413 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed dye laser treatment
Number of subjects: 0
Study 22228413 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 22228449 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib 50 mg/day for 4 weeks followed by 2 weeks of rest
Number of subjects: 31
Study 22228827 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-based cognitive-behavioral therapy (CBT) for depression in Parkinson disease, provided for 10 weeks, supplemented with 4 phone-based caregiver educational sessions.
Number of subjects: 21
Study 22229310 — intervention group
Group type: EXPERIMENTAL
Intervention: NicVAX (nicotine vaccine)
Number of subjects: 0
Study 22229310 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-nicotine antibodies
Number of subjects: 0
Study 22230151 — intervention group
Group type: EXPERIMENTAL
Intervention: Stent thrombosis at coronary bifurcations
Number of subjects: 20
Study 22231150 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Number of subjects: 0
Study 22231150 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral opioid analgesia (morphine or hydromorphone) via patient-controlled analgesia (PCA)
Number of subjects: 0
Study 22231150 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydromorphone
Number of subjects: 0
Study 22231150 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 0
Study 22231150 — intervention group
Group type: COMPARATOR
Intervention: Intravenous fluids
Number of subjects: 0
Study 22231150 — intervention group
Group type: COMPARATOR
Intervention: Incentive spirometry
Number of subjects: 0
Study 22232031 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal administration of cultured autologous bone marrow stromal cells (BMSCs)
Number of subjects: 5
Study 22232483 — intervention group
Group type: EXPERIMENTAL
Intervention: β-Blocking treatment
Number of subjects: 0
Study 22232483 — intervention group
Group type: COMPARATOR
Intervention: Control group (no β-Blocking treatment)
Number of subjects: 0
Study 22233350 — intervention group
Group type: EXPERIMENTAL
Intervention: Entecavir
Number of subjects: 203
Study 22233455 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine plus Vitamin D
Number of subjects: 0
Study 22233455 — intervention group
Group type: COMPARATOR
Intervention: Memantine
Number of subjects: 0
Study 22233617 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment according to European guidelines on cardiovascular disease prevention
Number of subjects: 811
Study 22233617 — intervention group
Group type: COMPARATOR
Intervention: Control group (778 subjects)
Number of subjects: 811
Study 22233617 — intervention group
Group type: EXPERIMENTAL
Intervention: PAD group
Number of subjects: 811
Study 22233617 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 811
Study 22233865 — intervention group
Group type: EXPERIMENTAL
Intervention: Stem Cell Educator therapy
Number of subjects: 15
Study 22233865 — intervention group
Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 15
Study 22234149 — intervention group
Group type: EXPERIMENTAL
Intervention: Linagliptin (5 mg: 3159 patients; 10 mg: 160 patients)
Number of subjects: 5239
Study 22234149 — intervention group
Group type: COMPARATOR
Intervention: Comparators (placebo: 977 patients; glimepiride 1-4 mg: 781 patients; voglibose 0.6 mg: 162 patients)
Number of subjects: 5239
Study 22234149 — intervention group
Group type: EXPERIMENTAL
Intervention: Linagliptin
Number of subjects: 5239
Study 22234149 — intervention group
Group type: COMPARATOR
Intervention: Comparators
Number of subjects: 5239
Study 22234282 — intervention group
Group type: EXPERIMENTAL
Intervention: Binge eating (self-reported presence at baseline)
Number of subjects: 180
Study 22234714 — intervention group
Group type: EXPERIMENTAL
Intervention: Reading rehabilitation program
Number of subjects: 18
Study 22234716 — intervention group
Group type: EXPERIMENTAL
Intervention: Complementary and alternative medicine (CAM) users
Number of subjects: 401
Study 22234716 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage therapy (most preferred CAM option)
Number of subjects: 401
Study 22234716 — intervention group
Group type: EXPERIMENTAL
Intervention: Chiropractic care (least preferred CAM option)
Number of subjects: 401
Study 22234716 — intervention group
Group type: COMPARATOR
Intervention: CAM users vs nonusers
Number of subjects: 401
Study 22235096 — intervention group
Group type: EXPERIMENTAL
Intervention: OXi4503 (combretastatin A1 diphosphate, CA1P) administered intravenously at escalating doses from 0.06 to 1.92 mg/m(2), then expanded cohorts to 15.4 mg/m(2) on days 1, 8, and 15 every 28 days.
Number of subjects: 43
Study 22235096 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum tolerated dose of OXi4503 was 8.5 mg/m(2), escalation to 14 mg/m(2) was possible with temporary reversible cerebrovascular toxicity.
Number of subjects: 43
Study 22235243 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly 135 µg peginterferon-α 2a plus ribavirin 400 mg twice daily during 20 weeks
Number of subjects: 58
Study 22235252 — intervention group
Group type: EXPERIMENTAL
Intervention: Undifferentiated MDD
Number of subjects: 89
Study 22235252 — intervention group
Group type: EXPERIMENTAL
Intervention: Atypical MDD
Number of subjects: 89
Study 22235252 — intervention group
Group type: EXPERIMENTAL
Intervention: Melancholic MDD
Number of subjects: 89
Study 22235252 — intervention group
Group type: COMPARATOR
Intervention: Healthy Controls
Number of subjects: 89
Study 22236356 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide BID
Number of subjects: 4344
Study 22236356 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide QW
Number of subjects: 4344
Study 22236356 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 4344
Study 22236384 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous bone-marrow-derived mesenchymal stem cells (1·6×10(6) cells per kg bodyweight, range 1·1-2·0)
Number of subjects: 10
Study 22236392 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-session psychological intervention including medical information, coping skills promotion, and a psychoeducational booklet for parents.
Number of subjects: 30
Study 22236392 — intervention group
Group type: COMPARATOR
Intervention: Active control group with standard psychosocial care.
Number of subjects: 30
Study 22236508 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive testing (intracoronary acetylcholine administration, fast atrial pacing)
Number of subjects: 718
Study 22236508 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive testing
Number of subjects: 718
Study 22237988 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesothelin expression in BE tissue with high-grade dysplasia
Number of subjects: 125
Study 22237988 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesothelin expression in EAC tumors
Number of subjects: 125
Study 22237988 — intervention group
Group type: COMPARATOR
Intervention: Mesothelin expression in EAC tumors with BE vs. without BE
Number of subjects: 125
Study 22237988 — intervention group
Group type: EXPERIMENTAL
Intervention: Soluble mesothelin-related peptide (SMRP) levels in EAC patients
Number of subjects: 125
Study 22237988 — intervention group
Group type: COMPARATOR
Intervention: SMRP levels in patients with acid reflux and/or BE
Number of subjects: 125
Study 22238003 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise program (3 times/week; 3 sets, 6-8 repetitions at 75-80% of the 1-repetition maximum)
Number of subjects: 237
Study 22238693 — intervention group
Group type: EXPERIMENTAL
Intervention: Pronto-7™ monitor
Number of subjects: 600
Study 22238693 — intervention group
Group type: EXPERIMENTAL
Intervention: NBM-200MP™ monitor
Number of subjects: 600
Study 22239832 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid tap test (TT)
Number of subjects: 100
Study 22240751 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 22241828 — intervention group
Group type: EXPERIMENTAL
Intervention: QSU-Brief questionnaire administered to Black light smokers
Number of subjects: 540
Study 22244041 — intervention group
Group type: COMPARATOR
Intervention: Normal weight children (nw)
Number of subjects: 578
Study 22244041 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight children (ow)
Number of subjects: 578
Study 22244041 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese children (ob)
Number of subjects: 578
Study 22244041 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher physical inactivity
Number of subjects: 578
Study 22244041 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher BMI
Number of subjects: 578
Study 22244041 — intervention group
Group type: EXPERIMENTAL
Intervention: Wider venular diameters
Number of subjects: 578
Study 22244041 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pressure
Number of subjects: 578
Study 22244076 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed (standard vitamin and dexamethasone supplementation)
Number of subjects: 521
Study 22244711 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithrombotic medications continued
Number of subjects: 177
Study 22244711 — intervention group
Group type: COMPARATOR
Intervention: Antithrombotic medications temporarily discontinued
Number of subjects: 177
Study 22245983 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual energy intake
Number of subjects: 252
Study 22245983 — intervention group
Group type: EXPERIMENTAL
Intervention: Laboratory energy intake
Number of subjects: 252
Study 22246176 — intervention group
Group type: EXPERIMENTAL
Intervention: Shift work model (intensivists working 7 day shifts)
Number of subjects: 501
Study 22246176 — intervention group
Group type: COMPARATOR
Intervention: Standard model (one intensivist worked for 7 days, taking night call from home)
Number of subjects: 501
Study 22246176 — intervention group
Group type: EXPERIMENTAL
Intervention: Shift work model
Number of subjects: 501
Study 22246176 — intervention group
Group type: EXPERIMENTAL
Intervention: Nighttime housestaff under shift work model
Number of subjects: 501
Study 22246178 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin use
Number of subjects: 0
Study 22246178 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin pretreatment in mice
Number of subjects: 0
Study 22246178 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin administration
Number of subjects: 0
Study 22246178 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 0
Study 22247403 — intervention group
Group type: EXPERIMENTAL
Intervention: Hippotherapy (45-minute sessions twice per week for 6 weeks)
Number of subjects: 16
Study 22247754 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic factors assessed using the Illumina Human660 W Genotyping BeadChip
Number of subjects: 1006
Study 22247754 — intervention group
Group type: COMPARATOR
Intervention: Cohort of individuals with ICD who did not experience LTA (controls)
Number of subjects: 1006
Study 22248486 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 IU/day of vitamin D3 supplementation
Number of subjects: 49
Study 22248486 — intervention group
Group type: COMPARATOR
Intervention: Cord serum 25(OH)D levels
Number of subjects: 49
Study 22248486 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 49
Study 22248486 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily vitamin D intake of 400 IU
Number of subjects: 49
Study 22248602 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholangioscopy-guided mini-forceps biopsies
Number of subjects: 26
Study 22248602 — intervention group
Group type: COMPARATOR
Intervention: Standard cytology brushings
Number of subjects: 26
Study 22248602 — intervention group
Group type: COMPARATOR
Intervention: Standard forceps biopsies
Number of subjects: 26
Study 22248721 — intervention group
Group type: EXPERIMENTAL
Intervention: Platinum-based compounds (PBCs) as single agents
Number of subjects: 0
Study 22248721 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin/carboplatin combined with taxanes
Number of subjects: 0
Study 22248721 — intervention group
Group type: EXPERIMENTAL
Intervention: PBCs combined with vinorelbine
Number of subjects: 0
Study 22248721 — intervention group
Group type: EXPERIMENTAL
Intervention: PBCs combined with etoposide
Number of subjects: 0
Study 22248721 — intervention group
Group type: EXPERIMENTAL
Intervention: PBCs combined with anthracyclines
Number of subjects: 0
Study 22248721 — intervention group
Group type: EXPERIMENTAL
Intervention: PBCs combined with trastuzumab
Number of subjects: 0
Study 22248721 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin or carboplatin with novel targeted therapeutics
Number of subjects: 0
Study 22249106 — intervention group
Group type: EXPERIMENTAL
Intervention: Tigecycline 0.75 mg/kg
Number of subjects: 58
Study 22249106 — intervention group
Group type: EXPERIMENTAL
Intervention: Tigecycline 1 mg/kg
Number of subjects: 58
Study 22249106 — intervention group
Group type: EXPERIMENTAL
Intervention: Tigecycline 1.25 mg/kg
Number of subjects: 58
Study 22249106 — intervention group
Group type: EXPERIMENTAL
Intervention: Tigecycline (all dosages)
Number of subjects: 58
Study 22249106 — intervention group
Group type: EXPERIMENTAL
Intervention: Tigecycline 1.2 mg/kg q12h (predicted)
Number of subjects: 58
Study 22249355 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60-120 mg per day
Number of subjects: 164
Study 22249355 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 164
Study 22249355 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine in patients with major depressive disorder (MDD)
Number of subjects: 164
Study 22249367 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated CD169+CD14+ monocytes during rejection in group B
Number of subjects: 56
Study 22249367 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated CD169+CD14+ monocytes during infection/inflammation in group D
Number of subjects: 56
Study 22249367 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated monocytes before ITx in rejectors
Number of subjects: 56
Study 22249367 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated monocytes during acute cellular rejection in rejectors
Number of subjects: 56
Study 22249367 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of activated monocytes with allospecific CD154+ T-cytotoxic memory cells
Number of subjects: 56
Study 22249367 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of activated monocytes with allospecific CD154+ B cells
Number of subjects: 56
Study 22249430 — intervention group
Group type: EXPERIMENTAL
Intervention: Dacomitinib 15 mg QD
Number of subjects: 13
Study 22249430 — intervention group
Group type: EXPERIMENTAL
Intervention: Dacomitinib 30 mg QD
Number of subjects: 13
Study 22249430 — intervention group
Group type: EXPERIMENTAL
Intervention: Dacomitinib 45 mg QD
Number of subjects: 13
Study 22250143 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual autopsy
Number of subjects: 285
Study 22250143 — intervention group
Group type: COMPARATOR
Intervention: Medical autopsy
Number of subjects: 285
Study 22250143 — intervention group
Group type: EXPERIMENTAL
Intervention: Any autopsy method
Number of subjects: 285
Study 22250143 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual autopsy only
Number of subjects: 285
Study 22250979 — intervention group
Group type: EXPERIMENTAL
Intervention: Indinavir/ritonavir (IDV/r) 600/100 mg plus lamivudine and stavudine administered every 12 hours (bid)
Number of subjects: 18
Study 22250979 — intervention group
Group type: EXPERIMENTAL
Intervention: Indinavir/ritonavir (IDV/r) treatment
Number of subjects: 18
Study 22250979 — intervention group
Group type: EXPERIMENTAL
Intervention: Indinavir/ritonavir (IDV/r) treatment with concomitant rifampicin
Number of subjects: 18
Study 22252944 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher ghrelin secretion in amenorrheic athletes (AA)
Number of subjects: 3
Study 22252944 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower leptin secretion in amenorrheic athletes (AA)
Number of subjects: 3
Study 22252944 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower LH secretion in amenorrheic athletes (AA)
Number of subjects: 3
Study 22252944 — intervention group
Group type: EXPERIMENTAL
Intervention: Association of body fat with hormone levels
Number of subjects: 3
Study 22252944 — intervention group
Group type: EXPERIMENTAL
Intervention: Regression model findings
Number of subjects: 3
Study 22253412 — intervention group
Group type: EXPERIMENTAL
Intervention: Synchronous bevacizumab and erlotinib with concurrent cisplatin and twice daily radiotherapy
Number of subjects: 29
Study 22253485 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab therapy
Number of subjects: 65
Study 22254197 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiographic examination
Number of subjects: 803
Study 22256804 — intervention group
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Number of subjects: 35
Study 22256804 — intervention group
Group type: EXPERIMENTAL
Intervention: Vemurafenib analogue PLX4720
Number of subjects: 35
Study 22257420 — intervention group
Group type: EXPERIMENTAL
Intervention: Family history of diabetes and CHD and/or stroke (Group 3)
Number of subjects: 2081
Study 22257420 — intervention group
Group type: EXPERIMENTAL
Intervention: Family history of diabetes alone (Group 2)
Number of subjects: 2081
Study 22257420 — intervention group
Group type: COMPARATOR
Intervention: No family history of diabetes, CHD or stroke (Group 1)
Number of subjects: 2081
Study 22258268 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased dietary sodium intake of 1000 mg/d
Number of subjects: 286
Study 22258268 — intervention group
Group type: EXPERIMENTAL
Intervention: Top quintile dietary sodium consumption (>1456 mg/d)
Number of subjects: 286
Study 22258268 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000-mg/d difference in dietary sodium between brothers
Number of subjects: 286
Study 22258271 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluten-free diet (GFD) with controlled ingestion of a fixed amount of gluten
Number of subjects: 0
Study 22258271 — intervention group
Group type: COMPARATOR
Intervention: Normal gluten-containing diet
Number of subjects: 0
Study 22258271 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluten-free diet (GFD) with ingestion of <100 mg gluten/d
Number of subjects: 0
Study 22258271 — intervention group
Group type: EXPERIMENTAL
Intervention: GFD infringement detection in CD patients
Number of subjects: 0
Study 22258485 — intervention group
Group type: EXPERIMENTAL
Intervention: T-SPOT.TB
Number of subjects: 429
Study 22258485 — intervention group
Group type: EXPERIMENTAL
Intervention: QTF-Gold IT
Number of subjects: 429
Study 22258485 — intervention group
Group type: COMPARATOR
Intervention: TST
Number of subjects: 429
Study 22258485 — intervention group
Group type: EXPERIMENTAL
Intervention: IGRA tests (one of the tests)
Number of subjects: 429
Study 22258545 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatase inhibitor (letrozole 12.5 mg/day for 3 days)
Number of subjects: 16
Study 22259028 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib 50 mg daily dose
Number of subjects: 1
Study 22260199 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal block using 10 mg 0.5% (w/v) bupivacaine
Number of subjects: 38
Study 22261507 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal height at age 4 years
Number of subjects: 119
Study 22261507 — intervention group
Group type: COMPARATOR
Intervention: Height <-1 SD
Number of subjects: 119